Company Filing History:
1 out of 512 
1 out of 8 Years Active: 2025
Title: Amaia Arruabarrena Aristorena: Innovator in Cancer Therapy
Introduction
Amaia Arruabarrena Aristorena is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer therapy through her innovative research and development of targeted drug delivery systems. Her work focuses on the development of PI3K inhibitors, which are crucial in the treatment of various proliferative diseases, including cancer.
Latest Patents
Amaia holds a patent for "PI3K inhibitors and uses thereof." This patent represents a significant advancement in cancer therapy by introducing a new, targeted drug delivery paradigm. The patent details compounds, such as those of Formula (I) and (II), along with their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs. These compounds are specifically designed as PI3K (e.g., PI3Kα) inhibitors, making them valuable for the treatment and prevention of various diseases, particularly cancer. Additionally, the patent discusses nanoparticles and nanogels that encapsulate these compounds for targeted delivery to cancer cells or tumors.
Career Highlights
Amaia has worked at prestigious institutions, including the Sloan Kettering Institute for Cancer Research and the Tri-Institutional Therapeutics Discovery Institute. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research in cancer treatment.
Collaborations
Throughout her career, Amaia has collaborated with notable colleagues, including Makoto Fushimi and Maurizio Scaltriti. These partnerships have further enhanced her research and development efforts in the field of cancer therapy.
Conclusion
Amaia Arruabarrena Aristorena is a trailblazer in the development of innovative cancer therapies through her work on PI3K inhibitors. Her contributions to targeted drug delivery systems are paving the way for more effective treatments for cancer patients.